<a href=Pfizer” height=”165″ src=”https://www.drugdevelopment-technology.com/wp-content/uploads/static-progressive/nri/pharma/news/220px-Pfizer_world_HQ_jeh.JPG” style=”padding: 10px” width=”220″ />

Merck and Pfizer will collaborate on the clinical development and commercialisation of ertugliflozin, an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes.

The agreement also includes the development and commercialisation of ertugliflozin-containing fixed-dose combinations with metformin and Januvia (sitagliptin) tablets.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Pfizer primary care president and general manager John Young said; "Through this collaboration, we believe we can build on Merck’s leadership position in diabetes care with the introduction of ertugliflozin, an innovative SGLT2 inhibitor discovered by Pfizer scientists."

Ertugliflozin, which was developed by Pfizer, is Phase III ready, with trials planned for later this year.

The rights to Merck’s existing portfolio of sitagliptin-containing products will be retained by the company.

Pfizer has earned upfront payment and milestones of $60m and is eligible for additional payments based on pre-specified future clinical, regulatory and commercial milestones.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Potential revenues and certain costs will be shared by Merck and Pfizer on a 60% / 40% basis.

Merck Research Laboratories senior vice president and diabetes and endocrinology franchise head Nancy Thornberry said; "We believe ertugliflozin has the potential to complement our strong portfolio of investigational and marketed products, and we look forward to collaborating with Pfizer on its development.".

Image: Merck and Pfizer will co-develop Ertugliflozin investigational medicine for type 2 diabetes. Photo: Courtesy of Jim Henderson.